Clinical Updates & Insights

Our clinical updates provide you with timely information about Memorial Sloan Kettering’s new treatment approaches, key clinical trials, and innovations in detecting and treating many cancers.

233 Clinical Updates found
Bill Tap, Chief of MSK's Sarcoma Medical Oncology Service
The combination immunotherapy of talimogene laherparepvec (T-VEC) and pembrolizumab met its primary endpoint of objective response rate at 24 weeks in our phase II clinical trial in patients with advanced sarcoma.
Surgery at MSK
Memorial Sloan Kettering has convened a COVID-19 Operating Room Executive Committee to scrutinize all surgical cases and determine whether they were truly essential and to review needs, resources, and ICU availability.
CAR T cells attacking cancer
Treatment with chimeric antigen receptor T cell therapy should proceed in patients with B cell non-Hodgkin lymphomas and B cell acute lymphocytic leukemia, despite Covid-19 according to the CAR T Cell Consortium, a collaboration of investigators from eight U.S. academic institutions.
Breast radiation therapy
During the early days of the COVID-19 outbreak, a team of radiation oncologists specializing in breast cancer management at Memorial Sloan Kettering Cancer Center reviewed the literature and established recommendations for the safe use of hypofractionated and abbreviated radiation regimens for our patients with breast cancer.
Patient in scanner
The pandemic has raised important issues for clinicians, and, after weighing the risks and benefits, the Colorectal Disease Management Team at MSK decided that all patients with locally advanced colorectal cancer will be treated with short-course radiation therapy rather than standard long-course chemoradiation therapy.
Babak J. Mehrara, MD
For the past five years, we have prospectively evaluated patients with secondary lymphedema of the upper extremity who presented for surgical consultation at Memorial Sloan Kettering Cancer Center (MSK).
T Cell attacking cancer cell
Older, vulnerable patients with relapsed/refractory large B cell lymphoma should receive the same consideration for CAR T cell therapy as younger patients.
Dr. Joseph Disa
When comparing options for immediate breast reconstruction after mastectomy, cost analyses should include patient-reported outcome (PRO) measures, such as BREAST-Q scales and complication rates.
Dr Joachim Yahalom
Very low-dose radiotherapy (VLDRT) is effective for treating grade 3A follicular lymphoma and provides patients with a shorter treatment course and fewer side effects.
Breast surgeon Dr. Melissa Pilewskie
Clinical Update
Increased breast density, but not BMI, is an additional risk factor for breast cancer in women with lobular carcinoma in situ (LCIS).